Prävention des Typ-2-Diabetes

• Literatur

• 1 Rathmann W, Haastert B, Icks A et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46: 182-189
• 2 Massi-Benedetti M. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 2002; 45: S1-S4
• 3 Icks A, Rathmann W, Haastert B et al. ; KORA Study Group Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a “real world” routine healthcare setting: model based on the KORA Survey 2000. Diabet Med 2007; 24: 473-480
• 4 Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887
• 5 Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 2011; 60: 2011-2017
• 6 Ketterer C, Tschritter O, Preissl H et al. Insulin sensitivity of the human brain. Diabetes Res Clin Pract 2011; 93 (Suppl. 01) S47-S51
• 7 Staiger H, Machicao F, Fritsche A et al. Pathomechanisms of type 2 diabetes genes. Endocr Rev 2009; 30: 557-585
• 8 Müssig K, Staiger H, Machicao F et al. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 2010; 53: 2289-2297
• 9 Gerstein HC, Santaguida P, Raina P et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305-312
• 10 Tabák AG, Herder C, Rathmann W et al. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279-2290
• 11 Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
• 12 Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
• 13 Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544
• 14 Ramachandran A, Snehalatha C, Mary S et al. ; Indian Diabetes Prevention Programme (IDPP) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-297
• 15 Lindström J, Ilanne-Parikka P, Peltonen M et al. ; Finnish Diabetes Prevention Study Group Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679
• 16 Lindström J, Peltonen M, Eriksson JG et al. ; for the Finnish Diabetes Prevention Study (DPS) Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2012; 24 [Epub ahead of print]
• 17 Knowler WC, Fowler SE, Hamman RF et al. ; Diabetes Prevention Program Research Group 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686
• 18 Kitabchi AE, Temprosa M, Knowler WC et al. ; Diabetes Prevention Program Research Group Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414
• 19 Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 143: 251-264
• 20 Herman WH, Hoerger TJ, Brandle M et al. ; Diabetes Prevention Program Research Group The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 323-332
• 21 Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012; 35: 723-730
• 22 Lindgren P, Lindström J, Tuomilehto J et al. ; DPS Study Group Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care 2007; 23: 177-183
• 23 Carlsson LM, Peltonen M, Ahlin S et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704
• 24 Gerstein HC, Yusuf S, Bosch J et al. ; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105 . Erratum in: Lancet 2006; 368: 1770
• 25 DeFronzo RA, Tripathy D, Schwenke DC et al. ; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-1115
• 26 Gerstein HC, Bosch J, Dagenais GR et al. ; ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328
• 27 Perreault L, Pan Q, Mather KJ et al. ; Diabetes Prevention Program Research Group Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379: 2243-2251
• 28 Stefan N, Fritsche A, Häring HU. Individualized prevention of type 2 diabetes. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009; 52: 677-682